Janki Patel1, Ricki Bettencourt2, Jeffrey Cui3, Joanie Salotti4, Jonathan Hooker5, Archana Bhatt3, Carolyn Hernandez3, Phirum Nguyen4, Hamed Aryafar5, Mark Valasek6, William Haufe5, Catherine Hooker5, Lisa Richards4, Claude B Sirlin5, Rohit Loomba7. 1. Department of Internal Medicine, University of California at San Diego, La Jolla, CA, USA. 2. NAFLD Translational Research Unit, Department of Medicine, University of California at San Diego, La Jolla, CA, USA Division of Epidemiology, Department of Family and Preventive Medicine, University of California at San Diego, La Jolla, CA, USA. 3. NAFLD Translational Research Unit, Department of Medicine, University of California at San Diego, La Jolla, CA, USA. 4. NAFLD Translational Research Unit, Department of Medicine, University of California at San Diego, La Jolla, CA, USA Division of Gastroenterology, Department of Medicine, University of California at San Diego, La Jolla, CA, USA. 5. Liver Imaging Group, Department of Radiology, University of California at San Diego, La Jolla, CA, USA. 6. Department of Pathology, University of California at San Diego, La Jolla, CA, USA. 7. NAFLD Translational Research Unit, Division of Gastroenterology and Epidemiology, University of California at San Diego, 9500 Gilman Drive, MC 0063, La Jolla, CA 92093, USA.
Abstract
BACKGROUND:Magnetic resonance imaging-estimated proton-density-fat-fraction (MRI-PDFF) has been shown to be a noninvasive, accurate and reproducible imaging-based biomarker for assessing steatosis and treatment response in nonalcoholic steatohepatitis (NASH) clinical trials. However, there are no data on the magnitude of MRI-PDFF reduction corresponding to histologic response in the setting of a NASH clinical trial. The aim of this study was to quantitatively compare the magnitude of MRI-PDFF reduction between histologic responders versus histologic nonresponders in NASH patients. METHODS: This study is a secondary analysis of the MOZART trial, which included 50 patients with biopsy-proven NASH randomized toezetimibe 10 mg/day orally or placebo for 24 weeks. The primary aim was to perform a head-to-head comparative analysis of histologic responders [defined as a ⩾2-point reduction in the nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) without worsening fibrosis] versus nonresponders, and the corresponding quantitative change in liver fat content measured via MRI-PDFF. RESULTS: Of the 35 patients who underwent paired liver biopsy and MRI-PDFF assessment at the beginning and end of treatment, 10 demonstrated a histologic response. Compared with histologic nonresponders, histologic responders had a statistically significant reduction in MRI-PDFF of -4.1% ± 4.9 versus -0.6 ± 4.1 (p < 0.04) with a mean relative percent change of -29.3% ± 33.0 versus +2.0% ± 24.0 (p < 0.004), respectively. CONCLUSIONS: Utilizing paired MRI-PDFF and liver histology data, we demonstrate that a relative reduction of 29% in liver fat on MRI-PDFF is associated with a histologic response in NASH. After external validation by independent research groups, these results can be incorporated into designing future NASH clinical trials, especially those utilizing change in hepatic fat quantified by MRI-PDFF, as a treatment endpoint.
RCT Entities:
BACKGROUND: Magnetic resonance imaging-estimated proton-density-fat-fraction (MRI-PDFF) has been shown to be a noninvasive, accurate and reproducible imaging-based biomarker for assessing steatosis and treatment response in nonalcoholic steatohepatitis (NASH) clinical trials. However, there are no data on the magnitude of MRI-PDFF reduction corresponding to histologic response in the setting of a NASH clinical trial. The aim of this study was to quantitatively compare the magnitude of MRI-PDFF reduction between histologic responders versus histologic nonresponders in NASH patients. METHODS: This study is a secondary analysis of the MOZART trial, which included 50 patients with biopsy-proven NASH randomized to ezetimibe 10 mg/day orally or placebo for 24 weeks. The primary aim was to perform a head-to-head comparative analysis of histologic responders [defined as a ⩾2-point reduction in the nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) without worsening fibrosis] versus nonresponders, and the corresponding quantitative change in liver fat content measured via MRI-PDFF. RESULTS: Of the 35 patients who underwent paired liver biopsy and MRI-PDFF assessment at the beginning and end of treatment, 10 demonstrated a histologic response. Compared with histologic nonresponders, histologic responders had a statistically significant reduction in MRI-PDFF of -4.1% ± 4.9 versus -0.6 ± 4.1 (p < 0.04) with a mean relative percent change of -29.3% ± 33.0 versus +2.0% ± 24.0 (p < 0.004), respectively. CONCLUSIONS: Utilizing paired MRI-PDFF and liver histology data, we demonstrate that a relative reduction of 29% in liver fat on MRI-PDFF is associated with a histologic response in NASH. After external validation by independent research groups, these results can be incorporated into designing future NASH clinical trials, especially those utilizing change in hepatic fat quantified by MRI-PDFF, as a treatment endpoint.
Authors: Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley Journal: Hepatology Date: 2010-09 Impact factor: 17.425
Authors: Rohit Loomba; Nicholas Schork; Chi-Hua Chen; Ricki Bettencourt; Ana Bhatt; Brandon Ang; Phirum Nguyen; Carolyn Hernandez; Lisa Richards; Joanie Salotti; Steven Lin; Ekihiro Seki; Karen E Nelson; Claude B Sirlin; David Brenner Journal: Gastroenterology Date: 2015-08-20 Impact factor: 22.682
Authors: Geraldine H Kang; Irene Cruite; Masoud Shiehmorteza; Tanya Wolfson; Anthony C Gamst; Gavin Hamilton; Mark Bydder; Michael S Middleton; Claude B Sirlin Journal: J Magn Reson Imaging Date: 2011-07-18 Impact factor: 4.813
Authors: Rohit Loomba; Maria Abraham; Aynur Unalp; Laura Wilson; Joel Lavine; Ed Doo; Nathan M Bass Journal: Hepatology Date: 2012-07-26 Impact factor: 17.425
Authors: An Tang; Justin Tan; Mark Sun; Gavin Hamilton; Mark Bydder; Tanya Wolfson; Anthony C Gamst; Michael Middleton; Elizabeth M Brunt; Rohit Loomba; Joel E Lavine; Jeffrey B Schwimmer; Claude B Sirlin Journal: Radiology Date: 2013-02-04 Impact factor: 11.105
Authors: Michael S Middleton; Elhamy R Heba; Catherine A Hooker; Mustafa R Bashir; Kathryn J Fowler; Kumar Sandrasegaran; Elizabeth M Brunt; David E Kleiner; Edward Doo; Mark L Van Natta; Joel E Lavine; Brent A Neuschwander-Tetri; Arun Sanyal; Rohit Loomba; Claude B Sirlin Journal: Gastroenterology Date: 2017-06-15 Impact factor: 22.682
Authors: Takeshi Yokoo; Suraj D Serai; Ali Pirasteh; Mustafa R Bashir; Gavin Hamilton; Diego Hernando; Houchun H Hu; Holger Hetterich; Jens-Peter Kühn; Guido M Kukuk; Rohit Loomba; Michael S Middleton; Nancy A Obuchowski; Ji Soo Song; An Tang; Xinhuai Wu; Scott B Reeder; Claude B Sirlin Journal: Radiology Date: 2017-09-11 Impact factor: 11.105
Authors: Yingzhen N Zhang; Kathryn J Fowler; Gavin Hamilton; Jennifer Y Cui; Ethan Z Sy; Michelle Balanay; Jonathan C Hooker; Nikolaus Szeverenyi; Claude B Sirlin Journal: Br J Radiol Date: 2018-06-06 Impact factor: 3.039